QScreen AI (PMEDF) Stock Price, News & Analysis

Predictmedix AI Inc. (OTC Pink: PMEDF) is described as an emerging provider of rapid health screening and remote patient care solutions. The company is associated with artificial intelligence-enabled health and safety technology and AI-powered health and safety technology. Its shares are also referenced as trading on the Canadian Securities Exchange under the symbol PMED and on the Frankfurt exchange under the symbol 3QP or 3QP0.

According to multiple company news releases, Predictmedix AI develops proprietary artificial intelligence platforms that analyze physiological data patterns. Its SmartHealth AI stations and Safe Entry Stations use multispectral cameras to assess physiological signals and are described as capable of predicting a variety of health issues, including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, and various mental illnesses. The company also refers to a proprietary remote patient care platform intended to provide medical professionals with AI-powered tools to improve patient health outcomes.

Core AI Engine and Multi-Vertical Strategy

Predictmedix AI states that it has built a single proprietary Core AI Engine that underpins several growth verticals. In its corporate updates, the company outlines three main application areas for this engine:

• SmartHealth AI Stations for workplace, institutional, and healthcare screening, described as contactless screening systems that have undergone independent, multi-center clinical validation and are reported as demonstrating approximately 95% accuracy in detecting impairment, infectious disease, and multiple vital signs, with actual results noted as potentially varying.
• Clinical-Trial AI platforms focused on patient matching, simulation, and trial optimization. The company describes an adaptive AI engine designed to simulate, optimize, and predict outcomes across multi-site clinical trials, with features such as an adaptive simulation engine, patient-site optimization, cost and ROI modeling, interactive dashboards, and compliance-integrated AI.
• Consumer mobile applications for vital and wellness screening, including a mobile diabetes screening platform that uses AI-driven facial and biometric analysis via smartphone to generate instant diabetic risk scoring, with India identified as an initial launch market in one news release.

The company characterizes this multi-vertical approach as a way to apply shared datasets, adaptive learning systems, and quantum-inspired computational techniques across multiple markets, using a unified intelligence framework shared with SmartHealth deployments and mobile applications.

Quantum-Inspired and AI-Driven Healthcare Focus

Predictmedix AI repeatedly highlights its work at the intersection of artificial intelligence, quantum-inspired computation, and digital healthcare. In several releases, the company states that it is integrating hybrid quantum-classical algorithms into its AI framework. These quantum-inspired approaches are described as supporting noise reduction, improved signal clarity, and bias reduction across diverse lighting conditions, skin tones, and occlusions, while running on standard computing hardware without specialized quantum devices.

The company also reports that its SmartHealth AI Stations have generated hundreds of thousands of real-world scans, which it describes as a proprietary, high-fidelity dataset used to refine AI models and support quantum-inspired enhancements. Internal and third-party assessments are cited in one release as measuring approximately 95% accuracy for vital-sign detection, with the qualification that actual results may vary.

Clinical-Trial AI Platform

In a dedicated announcement, Predictmedix AI presents its Clinical-Trial AI Platform as a "digital brain" for clinical trials. The platform is said to ingest and harmonize datasets such as patients, protocols, sites, historical outcomes, and costs, and to update analyses as new data becomes available. Described capabilities include:

• An adaptive simulation engine that runs scenario analyses and refreshes projections as enrollment and site-performance information changes.
• Patient-site optimization, where AI is used to recommend patient-site matching with the stated aim of improving recruitment and reducing dropouts.
• Cost and ROI modeling through proprietary algorithms that estimate potential budget impact alongside predicted clinical outcomes.
• Interactive dashboards with visualizations such as dynamic heatmaps and Sankey plots for risk, cost, and patient flow.
• Compliance-integrated AI that tracks data inputs and simulations to support audit and regulatory processes.

The company positions this platform as a software-as-a-service (SaaS) offering intended for pharmaceutical sponsors and contract research organizations, with references to potential paid pilot programs and private demonstrations.

Consumer and Mobile Health Applications

Predictmedix AI has announced plans and initiatives in consumer digital health. One news release describes a mobile diabetes screening platform designed to deliver rapid, non-invasive diabetic risk assessments using only a smartphone. The solution is said to rely on AI-driven facial and biometric analysis based on the company’s non-invasive screening platform, with features such as instant diabetic risk scoring, multilingual support, and data handling aligned with India’s Digital Personal Data Protection Act, as described in the release.

The company also refers to broader consumer mobile applications for scalable vital and wellness screening, which are intended to share the same Core AI Engine and imaging technology used in its SmartHealth and Safe Entry Stations.

Geographic and Market Activities

Company news releases reference Toronto, Ontario, as the location of corporate announcements. Predictmedix AI also reports participation in international investor and trade events, including the 25th MK Investment Conference in Munich, Germany, and European investor roadshows with events in Hungary, Croatia, and Serbia. In another release, the company notes its selection for an Official Canada Trade Mission to Mexico, with activities in Mexico City, Guadalajara, and Monterrey, focused on introducing its health and safety technologies to Mexican distributors, clients, and industry leaders.

In the mobile diabetes initiative, Predictmedix AI identifies India as an initial launch market for its smartphone-based diabetic screening platform. The company also mentions assessing regulatory requirements in multiple jurisdictions, including Southeast Asia, in connection with SmartHealth AI Station certification processes, as described in its multi-vertical strategy announcement.

Planned Name Change and Branding

In a news release, Predictmedix AI announces a proposed name change to QScreen AI Inc., with a planned new ticker symbol QAI, subject to regulatory approval by the Canadian Securities Exchange and other authorities. The company states that this rebranding is intended to reflect its focus on the fusion of quantum-inspired computing and AI in healthcare, and introduces the concept of "Quantum Screening" as part of its future identity. Until such changes are approved and implemented, the company continues to be referred to in the releases as Predictmedix AI Inc. with the existing symbols.

Capital Markets and Financing Activity

Several news releases describe non-brokered private placements. The company details offerings of units consisting of common shares and common share purchase warrants, with specified exercise prices and terms. Some tranches include insider participation, with references to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, and the use of exemptions from valuation and minority shareholder approval requirements based on the fair market value of insider participation relative to the company’s market capitalization.

These financings are presented as supporting the advancement of the Predictmedix Core AI Engine, SmartHealth AI Station certification initiatives, AI-powered clinical trial applications, B2C vital-scanning mobile platform development, and corporate functions such as regulatory compliance and investor engagement.

Positioning Within AI-Enabled Health and Safety

Across its communications, Predictmedix AI describes itself as operating at the convergence of AI, quantum-inspired computation, and healthcare. It emphasizes contactless screening, multispectral imaging, and AI-driven analysis of physiological data patterns as the basis for its solutions. The company’s stated strategy is to extend this technology base across enterprise health and safety, clinical-trial optimization, and consumer digital health, using shared data and algorithms to support multiple applications.

While the company’s sector classification in some external data sources is listed as Manufacturing with an industry description of "Software and Other Prerecorded Compact Disc, Tape, and Record Reproducing," the company’s own releases consistently describe its focus as AI-powered health screening, remote patient care platforms, and related digital health technologies.